ImmunoGen, Inc. (IMGN) News

ImmunoGen, Inc. (IMGN): $4.61

0.11 (+2.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter IMGN News Items

IMGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IMGN News Highlights

  • IMGN's 30 day story count now stands at 19.
  • Over the past 25 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • The most mentioned tickers in articles about IMGN are ADC, BEAT and DRUG.

Latest IMGN News From Around the Web

Below are the latest news stories about ImmunoGen Inc that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 25, 2022

ImmunoGen Reports Recent Progress and 2021 Financial Results

WALTHAM, Mass., February 25, 2022--ImmunoGen Reports Recent Progress and 2021 Financial Results

Yahoo | February 25, 2022

ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

WALTHAM, Mass., February 23, 2022--ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

Yahoo | February 23, 2022

ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B

ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.

Yahoo | February 16, 2022

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Yahoo | February 16, 2022

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

ImmunoGen Inc (NASDAQ: IMGN ) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY ) to grant exclusive rights to research, develop, and commercialize antibody-drug conjugates (ADCs) directed to targets selected by Lilly based on ImmunoGen''s camptothecin technology. Camptothecins are an important class of anticancer drugs targeting Type I topoisomerase. According to the deal, Lilly … Full story available on Benzinga.com

Benzinga | February 15, 2022

ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion

ImmunoGen Inc. shares jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co. of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Camptothecins are a class of cancer drugs. Under the terms of the deal, ImmunoGen will receive $13 million upfront and up to $32.5 million for meeting certain targets. "ImmunoGen is eligible to receive up to $1.7 billion in potential target program exercise fees and milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones," the company said in a statement. It will also be eligible for certain tiered royalties as a percentage of worldwide sales. ImmunoGen shares have fallen 47% in the last 12 months, while the S&P 500 has g...

MarketWatch | February 15, 2022

ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion

Business Wire | February 15, 2022

ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

WALTHAM, Mass., February 10, 2022--ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

Yahoo | February 10, 2022

Where Do Analysts Think The ImmunoGen Inc. (NASDAQ: IMGN) Is Going

ImmunoGen Inc. (NASDAQ:IMGN) price closed higher on Monday, February 07, jumping 3.95% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Stocks Register | February 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5832 seconds.